Table 3.
Risk of serious infant infections during the first year of life associated with biologics exposure in utero
| Infant serious infections | ||
| Parameter | OR (95% CI) | |
| Unadjusted | Biologics | 0.58 (0.18 to 1.85) |
| Model 1 | Biologics | 0.50 (0.16 to 1.60) |
| DMARDs/ immunosuppressants |
1.07 (0.81 to 1.43) | |
| Glucocorticoids | 1.46 (1.00 to 2.12) | |
| Model 2 | Biologics | 0.56 (0.17 to 1.81) |
| DMARDs/ immunosuppressants |
1.09 (0.81 to 1.45) | |
| Glucocorticoids | 1.13 (0.77 to 1.66) | |
| Female sex | 0.73 (0.60 to 0.89) | |
| Multiparity | 1.56 (1.25 to 1.95) | |
| Maternal antenatal visits | 0.97 (0.94 to 0.99) | |
| Prior delivery with anomaly | 2.04 (0.98 to 4.26) | |
| Prior delivery with low birth weight |
1.67 (1.05 to 2.64) | |
| Prior premature delivery | 1.73 (1.21 to 2.47) | |
| Maternal antidepressant use | 1.30 (0.97 to 1.75) | |
| Maternal anxiolytics use | 1.66 (1.15 to 2.40) | |
| Maternal rheumatoid arthritis diagnosis |
1.17 (0.93 to 1.47) | |
| Maternal asthma diagnosis | 2.00 (1.18 to 3.39) | |
| Apgar score at 1 min | 0.87 (0.83 to 0.92) | |
| Neighbourhood income quintile | 0.91 (0.85 to 0.98) | |
| Model 3 HDPS-matched cohort |
Biologics | 0.49 (0.15 to 1.62) |
DMARDs, disease-modifying antirheumatic drugs; HDPS, high-dimensional propensity score.